Global biopharma leader drives digital innovation, data
sciences, and next-generation automation approaches with Genedata's
cloud-based Biopharma Platform
BASEL,
Switzerland, July 31,
2024 /PRNewswire-PRWeb/ -- Genedata, a leading
provider of enterprise software solutions for biopharmaceutical
R&D, today announced that GSK, a leading biopharma company, has
extended the use of Genedata BiologicsĀ® to new application areas in
data sciences, analytics, and R&D automation.
Access to structured and organized data
from Genedata Biologics enables our data science, predictive
modelling, and AI/ML projects as we continue our work to optimize
the clinical effectiveness of our medicines. Steve Martin, Ph.D., VP and Head of Large
Molecule Discovery at GSK
"We've migrated our on-premise hosted version of Biologics to
Genedata's SaaS platform to leverage the various benefits that
cloud-hosting offers. We continue to integrate data workflows for
design, production, screening, characterization and engineering of
novel biotherapeutics whilst developing features to handle bi- and
multi-specific modalities," said Steve
Martin, Ph.D., VP and Head of Large Molecule Discovery. "At
GSK we use leading edge data and platform technologies to discover
and develop new medicines and vaccines better and faster to
positively impact the health of people at scale. Access to
structured and organized data from Genedata Biologics enables our
data science, predictive modelling, and AI/ML projects as we
continue our work to optimize the clinical effectiveness of our
medicines."
Since its initial deployment in 2013, Genedata Biologics has
become a core part of GSK's Large Molecule Discovery team's
antibody discovery data platform, automating lab operations and
data streams from diverse discovery projects. Genedata Biologics
directly integrates with GSK's automation systems to generate,
express, and purify large numbers of candidates, followed by
high-throughput characterization and lead evaluation. Automated
cloning and expression runs generate a substantial number of data
and metadata points that Genedata Biologics can store and help
cascade to downstream consumers across the organization.
The system offers real-time access to all critical data to GSK's
scientists, managers, and executives, which promotes synergies
within and across projects. The Genedata platform also enables
users across R&D to monitor program performance, resource and
project planning, and task prioritization.
"We are pleased that GSK, one of the leading innovators in the
development of novel biopharmaceuticals, has decided to expand the
use of Genedata Biologics as their foundation platform for guided
biotherapeutics discovery," said Othmar
Pfannes, Ph.D., CEO of Genedata. "Digital transformation is
opening new horizons in biopharmaceutical R&D, and we are
excited that our platform is helping GSK to develop innovative
biotherapies faster."
About Genedata
Genedata transforms data into intelligence with innovative software
solutions that incorporate extensive biopharma R&D domain
knowledge. Multinational biopharmaceutical organizations and
cutting-edge biotechs around the globe rely on Genedata to
digitalize and automate data-rich and complex R&D processes.
From early discovery all the way to the clinic, Genedata solutions
help maximize the ROI in R&D expenditure. Founded in 1997,
Genedata is headquartered in Basel,
Switzerland with additional offices in Boston, London, Munich, San
Francisco, Singapore, and
Tokyo.
http://www.genedata.com
LinkedIn | X | YouTube
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans,
events or performance are forward-looking statements that involve
risks and uncertainties, including risks associated with
uncertainties related to contract cancellations, developing risks,
competitive factors, uncertainties pertaining to customer orders,
demand for products and services, development of markets for the
Company's products and services. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to
release publicly the result of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
All product and service names mentioned are the trademarks of
their respective companies.
Media Contact
Allison Kurz, Genedata, +41 61
511 84 00, pr@genedata.com, www.genedata.com
View original content to download
multimedia:https://www.prweb.com/releases/gsk-leverages-genedata-biologics-as-end-to-end-automation-and-data-science-platform-302207516.html
SOURCE Genedata